CAN U READ? Chief Medical Officer managing clinical development which is having very positive reaction from peers in med. community: HE HAS NOTHING TO DO WITH PUBLIC RELATIONS.
Dr. Nejadnik will be responsible for managing all of Galena's clinical development programs, which consist of multiple mid- to late-stage clinical assets, including immunotherapy programs led by NeuVax(TM) (nelipepimut-S) and GALE-301 (Folate Binding Protein).
NeuVax is currently in a pivotal, Phase 3 clinical trial with several concurrent Phase 2 trials both as a single agent and in combination with other therapies. GALE-301 recently completed a Phase 2a clinical trial in ovarian and endometrial cancer.
So with that assumption that the co.'s guilty if it PR's you can be sure the shorts will continue to have a field day with this marked --
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.